AI Stock Analysis - Novo Nordisk (NVO)
Analysis generated January 16, 2026.
Novo Nordisk is a global healthcare company headquartered in Denmark, renowned for its leadership in diabetes care. The company operates in various therapeutic areas, including diabetes care, obesity care, hemophilia management, growth hormone therapy, and hormone replacement therapy. Novo Nordisk's innovative approach and commitment to clinical excellence have made it a pivotal player in the global pharmaceutical industry.
Stock Alerts - Novo Nordisk (NVO)
 |
Novo Nordisk | January 16 Price is up by 6.5% in the last 24h. |
|
Novo Nordisk | January 11 Job postings are down by 16% in the last couple of days. |
|
Novo Nordisk | January 7 Reddit mentions are up by 199% in the last 24h. |
|
Novo Nordisk | January 6 Reddit mentions are up by 325% in the last 24h. |
Download our app to get future alerts delivered in real-time.
Alternative Data for Novo Nordisk
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 300 | Sign up | Sign up | Sign up |
| Sentiment | 58 | Sign up | Sign up | Sign up |
| Webpage traffic | 733,000 | Sign up | Sign up | Sign up |
| Employee Rating | 80 | Sign up | Sign up | Sign up |
| Google Trends | 42 | Sign up | Sign up | Sign up |
| Patents | N/A | Sign up | Sign up | Sign up |
| 4chan Mentions | 1 | Sign up | Sign up | Sign up |
| Facebook Engagement | 25,334 | Sign up | Sign up | Sign up |
| Facebook Followers | 766,436 | Sign up | Sign up | Sign up |
| Instagram Followers | 177,478 | Sign up | Sign up | Sign up |
| Reddit Mentions | 36 | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 1,377 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 29,306 | Sign up | Sign up | Sign up |
| X Followers | 55,146 | Sign up | Sign up | Sign up |
| X Mentions | 267 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 43,900 | Sign up | Sign up | Sign up |
| News Mentions | 3 | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| Lobbying Cost | $647,000 | Sign up | Sign up | Sign up |
| Business Outlook | 60 | Sign up | Sign up | Sign up |
| Linkedin Employees | 65,871 | Sign up | Sign up | Sign up |
About Novo Nordisk
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents.
| Price | $62.33 |
| Target Price | Sign up |
| Volume | 43,380,000 |
| Market Cap | $277B |
| Year Range | $44.89 - $80.18 |
| Dividend Yield | 2.77% |
| PE Ratio | 17.17 |
| Analyst Rating | 57% buy |
| Industry | Drug Manufacturers |
In the news
 |
Novo Nordisk Launches Obesity Medicine Wegovy® (Semaglutide 2.4mg) (MAL24126014AZ) in Malaysia: A Key Advancement in the Fight Against Obesity and Cardiovascular Risks for People Living with OverweightJanuary 17 - Minimeinsights.com |
 |
European Stocks Post Fifth Weekly Advance; Novo Nordisk RisesJanuary 16 - Financial Post |
Novo Nordisk (NVO) is “in a Battle,” Says Jim CramerJanuary 16 - Yahoo Entertainment |
|
Novo Nordisk wins 3,071 prescriptions for Wegovy pill (NVO:NYSE) - Seeking AlphaJanuary 16 - Slashdot.org |
|
 |
Novo Nordisk shares rise 5% after Wegovy obesity pill has ‘solid’ launchJanuary 16 - CNBC |
 |
Novo Nordisk up 6% as UK approves higher dose of WegovyJanuary 16 - Biztoc.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '25 | 75B | 17.9B | 57.1B | 20B | 33.8B | 4.500 |
| Q2 '25 | 76.9B | 12.8B | 64B | 26.5B | 43.6B | 5.960 |
| Q1 '25 | 78.1B | 12.9B | 65.2B | 29B | 46B | 6.530 |
| Q4 '24 | 85.7B | 13B | 72.7B | 28.2B | 40.3B | 6.340 |
| Q3 '24 | 71.3B | 11.3B | 60B | 27.3B | 37.4B | 6.120 |
Insider Transactions View All
No recorded Insider transactions.
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$218.66 0% | 44 |
 |
Eli Lilly and CompanyLLY |
$1038.4 0% | 66 |
 |
PfizerPFE |
$25.65 0% | 51 |
 |
AstrazenecaAZN |
$94.43 0% | 47 |
 |
AbbVieABBV |
$214.35 0% | 49 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Lisa McClain |
Oct 22, 25 | Buy | $1K - $15K |
| Marjorie Taylor Greene |
Oct 21, 25 | Buy | $1K - $15K |
| Lisa McClain |
Sep 15, 25 | Sell | $1K - $15K |
Read more about Novo Nordisk (NVO) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, x followers, x mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
FAQ - Novo Nordisk
The Market Cap of Novo Nordisk is $277B.
As of today, Novo Nordisk's PE (Price to Earnings) ratio is 17.17.
Currently, the price of one share of Novo Nordisk stock is $62.33.
The NVO stock price chart above provides a comprehensive visual representation of Novo Nordisk's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Novo Nordisk shares. Our platform offers an up-to-date NVO stock price chart, along with technical data analysis and alternative data insights.
Yes, Novo Nordisk (NVO) offers dividends to its shareholders, with a dividend yield of 2.77%. This dividend yield represents Novo Nordisk's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering Novo Nordisk in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
Some of the similar stocks of Novo Nordisk are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and AbbVie.
